

Stimulation of glucose uptake in murine soleus muscle and adipocytes by 5-(4-phenoxybutoxy)psoralen (PAP-1) may be mediated by Kv1.5 rather than Kv1.3

Robert A. Ngala¹, Mohamed S. Zaibi, Kenneth Langlands, Claire J. Stocker, Jonathan R.S. Arch and Michael A. Cawthorne

Clare Laboratory, Buckingham Institute for Translational Medicine, University of Buckingham, Buckingham, UK

¹Current affiliation: Department of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology Kumasi, Ghana

ABSTRACT

Kv1 channels are shaker-related potassium channels that influence insulin sensitivity. Kv1.3^{-/-} mice are protected from diet-induced insulin resistance and some studies suggest that Kv1.3 inhibitors provide similar protection. However, it is unclear whether blockade of Kv1.3 in adipocytes or skeletal muscle increases glucose uptake. There is no evidence that the related channel Kv1.5 has any influence on insulin sensitivity and its expression in adipose tissue has not been reported. PAP-1 is a selective inhibitor of Kv1.3, with 23-fold, 32-fold and 125-fold lower potencies as an inhibitor of Kv1.5, Kv1.1 and Kv1.2 respectively. Soleus muscles from wild-type and genetically obese *ob/ob* mice were incubated with 2-deoxy[1-¹⁴C]-glucose for 45 min and formation of 2-deoxy[1-¹⁴C]-glucose-6-phosphate was measured. White adipocytes were incubated with D-[U-¹⁴C]-glucose for 1 h. TNF α and IL-6 secretion from white adipose tissue pieces were measured by enzyme-linked-immunoassay. In the absence of insulin, a high concentration (3 μ M) of PAP-1 stimulated 2-deoxy[1-¹⁴C]-glucose uptake in soleus muscle of wild-type and obese mice by 30% and 40% respectively, and in adipocytes by 20% and 50% respectively. PAP-1 also stimulated glucose uptake by adipocytes at the lower concentration of 1 μ M, but at 300 nM, which is still 150-fold higher than its EC50 value for inhibition of the Kv1.3 channel, it had no effect. In the presence of insulin, PAP-1 (3 μ M) had a significant effect only in adipocytes from obese mice. PAP-1 (3 μ M) reduced the secretion of TNF α by adipose tissue but had no effect on the secretion of IL-6. Expression of Kv1.1, Kv1.2, Kv1.3 and Kv1.5 was determined by RT-PCR. Kv1.3 and Kv1.5 mRNA were detected in liver, gastrocnemius muscle, soleus muscle and white adipose tissue from wild-type and *ob/ob* mice, except that Kv1.3 could not be detected in gastrocnemius muscle, nor Kv1.5 in liver, of wild-type mice. Expression of both genes was generally higher in liver and muscle of *ob/ob* mice compared to wild-type mice. Kv1.5 appeared to be expressed more highly than Kv1.3 in soleus muscle, adipose tissue and adipocytes of wild-type mice. Expression of Kv1.2 appeared to be similar to that of Kv1.3 in soleus muscle and adipose tissue, but Kv1.2 was undetectable in adipocytes. Kv1.1 could not be detected in soleus muscle, adipose tissue or adipocytes. We conclude

Submitted 10 September 2013
Accepted 17 September 2014
Published 7 October 2014

Corresponding author
Jonathan R.S. Arch,
jon.arch@buckingham.ac.uk

Academic editor
Rebecca Berdeaux

Additional Information and
Declarations can be found on
page 13

DOI 10.7717/peerj.614

© Copyright
2014 Ngala et al.

Distributed under
Creative Commons CC-BY 3.0

OPEN ACCESS

that inhibition of Kv1 channels by PAP-1 stimulates glucose uptake by adipocytes and soleus muscle of wild-type and *ob/ob* mice, and reduces the secretion of TNF α by adipose tissue. However, these effects are more likely due to inhibition of Kv1.5 than to inhibition of Kv1.3 channels.

Subjects Biochemistry, Diabetes and Endocrinology, Pharmacology, Metabolic Sciences

Keywords Potassium channel, PAP-1, Glucose uptake, Adipocyte, Soleus muscle, TNF α , Kv1.3, Kv1.5

INTRODUCTION

Kv1 channels are *shaker*-related, voltage-gated potassium channels (Gutman *et al.*, 2003). It has been proposed that compounds that block the Kv1.3 channel might be used in the treatment of type 2 diabetes and obesity (Choi & Hahn, 2010). Thus, a variant of the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance (Tschritter *et al.*, 2006), whereas Kv1.3^{-/-} mice were protected from diet-induced insulin resistance (Xu *et al.*, 2003) and obesity (Xu *et al.*, 2004). Some studies on inhibitors of Kv1.3 have demonstrated their ability to improve insulin sensitivity in mice (Xu *et al.*, 2004; Upadhyay *et al.*, 2013), but another has failed to show any benefit (Straub *et al.*, 2011).

In those studies in which improved insulin sensitivity has been shown, the tissues where the inhibitors have their primary action are uncertain. Kv1.3 channels in liver, postganglionic sympathetic neurons and brown adipose tissue are suggested targets (Upadhyay *et al.*, 2013). It is unclear whether white adipose tissue or skeletal muscle could be the primary site of action because there is disagreement as to whether Kv1.3 is expressed, particularly at the protein level, in these tissues (Grande *et al.*, 2003; Li *et al.*, 2006; Straub *et al.*, 2011; Upadhyay *et al.*, 2013). Nevertheless, the Kv1.3 inhibitor margatoxin decreased TNF α secretion by white adipose tissue from genetically obese (*ob/ob*) mice (Xu *et al.*, 2004), and administration of the highly selective Kv1.3 inhibitor ShK-186 for 45 days to mice fed on an obesity-inducing diet reduced TNF α mRNA in visceral adipose tissue (Upadhyay *et al.*, 2013). The target for the latter effect might be Kv1.3 channels in inflammatory cells, such as macrophages. Decreased inflammation of adipose tissue, including decreased secretion of TNF α , would be expected to improve insulin sensitivity (Calle & Fernandez, 2012).

As part of an investigation into the potential of Kv1.3 inhibitors for the treatment of type 2 diabetes, we have studied the effect of 5-(4-phenoxybutoxy)psoralen (PAP-1) on glucose uptake in white adipocytes and soleus muscle, and TNF α secretion by white adipocytes from wild-type and *ob/ob* mice. PAP-1 is a selective inhibitor of Kv1.3, being at least 23-fold selective as an inhibitor of Kv1.3 over other Kv1-family channels and 500-fold selective over Kv2.1, Kv3.1, Kv3.2 and Kv4.2 channels (Schmitz *et al.*, 2005). We report that a concentration of PAP-1 that is not selective for Kv1.3 stimulated glucose uptake and reduced TNF α secretion, but a lower concentration was ineffective, in agreement with the results of others (Beeton *et al.*, 2006; Straub *et al.*, 2011). This raised the question of the target for the non-selective concentration of PAP-1 and led us to investigate the expression

of Kv1.1, Kv1.2, Kv1.3 and Kv1.5 in mouse skeletal muscle and white adipose tissue. Kv1.5 is identified as a candidate mediator of the effects of PAP-1 on glucose uptake.

MATERIALS AND METHODS

Materials

All materials, including PAP-1 (>98% purity), were obtained from Sigma-Aldrich, Poole, UK, unless otherwise stated.

Animals

Housing and procedures were conducted in accordance with the UK Government Animal (Scientific procedures) Act 1986 and approved by the University of Buckingham Ethical review Board. C57Bl/6 and *ob/ob* mice (Harlan, Bicester, UK), aged 5–6 weeks, were fed standard laboratory chow *ad libitum* and euthanized 3–4 h after the onset of day light cycle, by a UK Government Animal Scientific Act 1986 schedule 1 method.

RT-PCR

Tissues isolated from wild-type and *ob/ob* female C57Bl/6 mice were homogenized in Tri-reagent using a ribolyser and total RNA prepared using QiagenTM minicolumns according to the manufacturer's instructions. One μ g total RNA was reverse-transcribed using avian reverse transcriptase and random priming in a 50 μ l reaction. Two μ l cDNA was subsequently used per 50 μ l PCR reaction as standard. GAPDH was chosen as the housekeeping genes because it showed consistent C_T values in adipose tissue, adipocytes and soleus muscle. Gene expression assays were obtained from Applied Biosystems Assay-on-Demand predesigned and optimized assays.

Subsequently, tissues were isolated from wild-type female C57Bl/6 mice. Total RNA was extracted and RT PCR performed by Real Time PCR using optimized Assay-on-Demand (Applied Biosystems) primers and probes for Kv1.1, 1.2, 1.3 and 1.5, relative to an endogenous GAPDH control ([Wargent et al., 2013](#)). Expression of each potassium channel was calculated relative to expression of GAPDH in each sample and then the expression levels of Kv1.2 and Kv1.5 were expressed relative to Kv1.3 in the same tissue ([Wargent et al., 2013](#)). Multiple Kv channels were not run in the same PCR reaction in order to prevent competition between the cDNA templates for the amplification reactants and to optimize reaction efficiency.

2-Deoxyglucose uptake by soleus muscle

Uptake of 2-deoxyglucose by the soleus muscle was measured by a method that we have described previously ([Ngala et al., 2008](#)). Soleus muscles were dissected from both hind legs of wild-type and *ob/ob* C57Bl/6 male mice. Distal and proximal tendons were tied under resting tension to stainless steel clips and pre-incubated for 60 min in Krebs-Henseleit bicarbonate buffer that contained 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5.5 mM glucose and 0.14% (w/v) fatty acid-free bovine serum albumin (BSA) at pH 7.4 and 37 °C. The buffer had been gassed previously with 95% O₂: 5% CO₂. They were then incubated for 45 min in fresh medium that also contained

2-deoxy[1-¹⁴C] glucose (56 mCi mmol⁻¹; 0.1 μCi ml⁻¹) and glucose (5.5 mM), with or without insulin (10 nM for wild-type mice and 100 nM for *ob/ob* mice) and PAP-1 (3 μM) or a combination of insulin and PAP-1.

At the end of the incubation, the muscles were digested with 1 M NaOH and the digest was neutralised with 1 M HCl. One portion of the mixture was treated with 2.5 volumes of 6% (w/v) perchloric acid to precipitate out proteins, leaving supernatant that contained both 2-deoxyglucose and 2-deoxyglucose-6-phosphate. Another portion was treated with 2.5 volumes of 2.68% (w/v) Ba(OH)₂ and 2.51% (w/v) ZnSO₄ to precipitate out 2-deoxyglucose-6-phosphate. Radioactivity incorporated into 2-deoxyglucose-6-phosphate was obtained from the difference between that in the two supernatants. 2-Deoxyglucose uptake was calculated by dividing radioactivity in 2-deoxyglucose-6-phosphate by the specific activity of 2-deoxyglucose.

Glucose uptake by adipocytes

Adipocytes were prepared from the parametrial fat pads of wild-type and *ob/ob* female mice by a method that we have described previously (Zaibi *et al.*, 2010). Tissue was minced and digested with collagenase type II in Krebs-Ringer HEPES buffer containing 10 mM HEPES, 1% bovine serum albumin (fraction V), 2.5 mM CaCl₂, 5.5 mM glucose and 200 nM adenosine at pH 7.4 and 37 °C. It was filtered through 250–300 μm nylon mesh. The infranatant was removed and the floating layer of adipocytes was washed four times with a fresh buffer. Adipocytes were concentrated to 40% of final volume of Krebs-Ringer HEPES buffer containing 5% BSA and 0.3 mM glucose and pre-incubated for 45 min under 95% O₂: 5% CO₂ before dispensing them into 300 μl polyethylene tubes for measurement of glucose uptake.

Glucose transport was measured as described previously (Kashiwagi, Huecksteadt & Foley, 1983). Adipocytes were incubated in Krebs-Ringer HEPES buffer containing BSA, 0.3 mM glucose and D-[U-¹⁴C] glucose (0.2 μmol/l; 0.2 μCi/ml), for 1 h at 37 °C in the absence or presence of different concentrations of PAP-1 and insulin. The reaction was stopped by separation of the cells through silicone oil and radioactivity in the cells was measured. Extracellular space was measured in parallel incubations using D-[U-¹⁴C] sucrose. Secretion is expressed per mg protein, determined using a method based on the Lowry assay (Bio-Rad, Hemel Hempstead, UK) or per g cells.

TNFα and IL-6 secretion

Adipose tissue from *ob/ob* and wild-type female mice was minced into pieces weighing about 200 mg and added to 0.3 ml Dulbecco's modified Eagle's medium and Ham's F-12 in a 1:1 mixture (both from Invitrogen, Paisley, UK), supplemented with 0.5% (w/v) endotoxin-free BSA. The incubation medium also contained 1 nM T3 and 5 mM glutamine. The plates were incubated with or without PAP-1 (3 μM) for 30 min. TNFα and IL-6 in the culture medium was assayed using murine ELISA kits (from Diaclone, Besançon, France for TNF; from Invitrogen for IL-6), following the manufacturer's instructions. Secretion is expressed per mg protein, determined using the Lowry assay.

Statistical analysis

Glucose uptake was calculated assuming that 2-deoxyglucose and glucose are not distinguished by uptake mechanisms. Data were analyzed by one- or two-way ANOVA followed by Fisher's least significant difference test, as described in the figure legends, using GraphPad Prism version 5 (GraphPad software, San Diego CA, USA). Results are expressed as means \pm SEM.

RESULTS

Glucose uptake in soleus muscle

Insulin (10 nM) and PAP-1 (3 μ M) stimulated 2-deoxyglucose uptake in soleus muscle from both wild-type and *ob/ob* mice (Fig. 1). The combination of insulin and PAP-1 also stimulated uptake compared to baseline in muscle from both wild-type and *ob/ob* mice ($P < 0.001$), but it did not have a significantly greater effect than either insulin or PAP-1 alone.

Glucose uptake in Adipocytes

PAP-1 (3 μ M) stimulated glucose in adipocytes from both wild-type and obese mice in the absence of insulin. In the presence of insulin at a range of concentrations, its effect was significant only in adipocytes from *ob/ob* mice (Fig. 2). In the absence of PAP-1, insulin stimulated uptake at concentrations of 0.5 nM and higher. The combination of insulin and PAP-1 stimulated uptake compared to baseline, but insulin did not stimulate glucose uptake significantly in the presence of PAP-1. A concentration–response curve conducted using adipocytes from wild-type mice in the absence of insulin showed significant effects of PAP-1 at 1 and 3 μ M, but not at lower concentrations (Fig. 3).

TNF α and IL-6 secretion

PAP-1 (3 μ M) suppressed the secretion of TNF α by 50% in adipocytes from both wild-type and *ob/ob* mice (Fig. 4). PAP-1 did not affect IL-6 secretion (results not shown). Surprisingly, secretion of TNF α from *ob/ob* adipocytes was lower than from wild-type adipocytes. Others have found a higher concentration of TNF α in adipocytes from *ob/ob* compared to wild-type adipocytes (Galvez, San Martin & Rodriguez, 2009).

Expression of Kv1mRNA

Using reverse transcription PCR, Kv1.3 mRNA was detected in liver, gastrocnemius muscle, soleus muscle and parametrial white adipose tissue of female wild-type and *ob/ob* mice, except that expression was not significantly above baseline in gastrocnemius muscle from wild-type mice (Fig. 5A). Expression was higher in liver, gastrocnemius muscle and soleus muscle, but not adipose tissue, of *ob/ob* mice compared to wild-type mice. Kv1.5 mRNA was detected in liver, gastrocnemius muscle, soleus muscle and parametrial white adipose tissue of female wild-type and *ob/ob* mice, except that expression could not be detected in livers from wild-type mice (Fig. 5B). Expression was higher in liver and soleus muscle of *ob/ob* mice compared to wild-type mice.




Figure 1 Effect of PAP-1 on glucose uptake in soleus muscles of male (A) wild-type and (B) *ob/ob* C57Bl6 mice. Muscles were treated with insulin (wild-type, 10 nM; *ob/ob*, 100 nM) or PAP-1 (3 μM) alone, or the combination of insulin and PAP-1. $n = 8$ mice per group for all columns. Data for each genotype were analyzed by one-way ANOVA followed by Fisher's least significant difference test. * $P < 0.05$; *** $P < 0.001$ for effect of PAP-1 compared to controls (Con). † $P < 0.05$; ‡‡‡ $P < 0.001$ for effect of insulin (Ins) compared to controls. ‡‡‡ $P < 0.001$ for the effect of the combination of PAP-1 and insulin compared to the absence of both compounds (Con). Note that in both wild-type and *ob/ob* mice, glucose uptake in the presence of the combination of PAP-1 and insulin was not significantly greater than in the absence of one of the compounds.




Figure 2 Effect of PAP-1 on glucose uptake in adipocytes of female (A) wild-type and (B) *ob/ob* C57Bl6 mice. Adipocytes were treated with insulin, PAP-1 (P, 3 μM) alone, or a combination of insulin and PAP-1. $n = 8$ mice per group for all columns. Data for each genotype were analyzed by two-way ANOVA (sources of variation: PAP-1 and insulin concentrations), followed by Fisher's least significant difference test, first for the paired columns at the same concentration of insulin, and second to test for an effect of insulin compared to the value obtained in the absence of insulin but in the presence of the same concentration (0 or 3 μM) of PAP-1. * $P < 0.05$; ** $P < 0.01$ for effect of PAP-1 compared to controls at the same concentration of insulin (C). † $P < 0.05$; †† $P < 0.01$; ††† $P < 0.001$ for effect of insulin compared to no insulin at the same concentration of PAP-1.




Figure 3 Concentration-response curve for the effect of PAP-1 on glucose uptake in the absence of insulin in adipocytes of female wild-type C57Bl6 mice. $n = 8$ mice per group for all columns. Data were analyzed by one-way ANOVA followed by Fisher's least significant difference test against the control value. * $P < 0.05$; *** $P < 0.001$ for effect of PAP-1 compared to baseline.




Figure 4 Effect of PAP-1 (3 μ M) on TNF α secretion by adipocytes from female wild-type and *ob/ob* mice. $n = 6$ mice per group for all columns. Data were \log_{10} -transformed so that variances were not significantly different between groups prior to analysis by two-way ANOVA (sources of variation: genotype and PAP-1 concentration), followed by Fisher's least significant difference test. * $P < 0.05$; ** $P < 0.01$ for effect of PAP-1 compared to control (Con).




Figure 5 Kv1.3 and Kv1.5 mRNA levels in liver, gastrocnemius, soleus and white adipose tissue of female (A) wild-type and (B) *ob/ob* mice. $n = 3$ mice for all columns. Expression of each potassium channel was calculated relative to expression of GAPDH in each sample. Data were \log_{10} -transformed prior to statistical analysis because the data obtained for Fig. 6 suggested that widely distributed data did not follow a normal distribution without this transformation. Analysis was by two-way ANOVA (sources of variation: genotype and tissue) for each gene, followed by Fisher's least significant difference test for each pair of wild-type and *ob/ob* values. Unpaired *t*-tests conducted on untransformed data gave the same significant differences. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ compared to wild-type mice.

After it was found that PAP-1 did not stimulate glucose uptake by adipocytes at concentrations that should be sufficient to activate Kv1.3, Real-Time PCR was used to detect mRNA for Kv1.1, Kv1.2, Kv1.3 and Kv1.5 in each of adipose tissue, adipocytes and soleus muscle. Assuming PCR reaction efficiencies of 1.0 for each gene, Kv1.5 was 30-, 15- and 78-fold more highly expressed than Kv1.3 in adipose tissue, adipocytes and soleus muscle respectively. Kv1.2 mRNA could not be detected in adipocytes and appeared to have lower expression than Kv1.3 in adipose tissue (Fig. 6). Kv1.1 could not be detected in adipose tissue, adipocytes or soleus muscle.




Figure 6 Relative expression of Kv1.2, Kv1.3 and Kv1.5 expression in (A) adipose tissue, (B) adipocytes and (C) soleus muscle of wild-type mice. Relative expression is given assuming that PCR reaction efficiencies were 1.0 for each gene. The expression of each Kv channel was expressed relative to GAPDH in the same sample and then relative to Kv1.3. $\Delta C_T \text{ GAPDH} - \Delta C_T \text{ Kv1.3}$ was 4.43 ± 0.31 for adipose tissue, 6.32 ± 0.34 for adipocytes and 9.8 ± 0.70 for soleus muscle ($n = 6$). Data were \log_{10} -transformed prior to statistical analysis because variances were clearly higher for Kv1.5, which was far more highly expressed than Kv1.2 or Kv1.3. Thus the Bartlett and F -tests showed (continued on next page...)

Figure 6 (...continued)

significant differences in variance for the adipose tissue and adipocyte data respectively when these data were not transformed. Analysis was by two-way ANOVA (sources of variation: gene and tissue), followed by Fisher's least significant difference test for adipose tissue and soleus muscle. Kv1.2 was undetectable in adipocytes, so Kv1.3 and Kv1.5 were compared by unpaired *t*-test. *n* = 4 mice for soleus muscle and 6 mice for adipose tissue and adipocytes. ***P* < 0.01; ****P* < 0.001.

DISCUSSION

A variety of evidence suggests that inhibition of Kv1.3 potassium channels might be effective in the treatment of insulin resistance, and thereby of type 2 diabetes (Choi & Hahn, 2010; Upadhyay *et al.*, 2013). This includes the finding that margatoxin, which inhibits members of the Kv1 family, including Kv1.3, lowered blood glucose in wild-type but not Kv1.3^{-/-} mice (Xu *et al.*, 2004). The authors linked this finding to the demonstration that margatoxin inhibited the secretion of TNF α and IL-6 by isolated adipocytes in adipose tissue and skeletal muscle after it was administered to wild-type but not Kv1.3^{-/-} mice. The tissues that contain the Kv1.3 channels at which the inhibitors exert their initial effects have not been well-defined, however.

We investigated whether the initial effects of Kv1.3 inhibitors might be on Kv1.3 channels in adipocytes or skeletal muscle using PAP-1. PAP-1 inhibits Kv1.3 with 33-fold selectivity over Kv1.1, 125-fold selectivity over Kv1.2 and 23-fold selectivity over Kv1.5 (Schmitz *et al.*, 2005). Inhibition of K channels might be expected to lead to cell depolarization and an increased demand for energy. We found that PAP-1 at the high concentration of 3 μ M stimulated glucose uptake in the absence of insulin in isolated soleus muscle and adipocytes from both wild-type and *ob/ob* mice. PAP-1 also stimulated glucose uptake in the presence of a range of concentrations of insulin in adipocytes from *ob/ob* mice. The same concentration of PAP-1 (3 μ M) also reduced the secretion of TNF α by adipocytes, potentially consistent with the suggestion of others (Xu *et al.*, 2004) that this is a mechanism by which blockade of Kv1.3 improves insulin sensitivity. However, when we investigated the concentration–response curve for the effect of PAP-1 on glucose uptake, we found that, whilst 1 μ M was effective, a concentration of 300 nM, which is still 150-fold higher than its EC₅₀ value for blockade of murine Kv1.3 (Schmitz *et al.*, 2005), had no effect on glucose uptake.

These experiments were conducted using tissues from female mice, except that soleus muscles from male mice were used for studying glucose uptake. These choices were in line with our previous work, allowing more accurate quality control by comparison with our historic data. Most studies of the effects of Kv1.3 inhibitors on metabolism have been conducted using male mice, but two studies have shown that deletion of the Kv1.3 gene has similar metabolic effects in male and female mice (Xu *et al.*, 2003; Tucker, Overton & Fadool, 2008).

Our results are consistent with a report that PAP-1 failed to lower blood glucose or enhance the glucose lowering effect of insulin when administered as a single dose or over five days to *ob/ob* or *db/db* mice in amounts that gave blood levels that would selectively block Kv1.3. Moreover, 10 nM PAP-1, a concentration fivefold higher than its IC₅₀ value for

inhibition of Kv1.3 channels, did not alter K⁺ currents in a human skeletal muscle cell line or glucose uptake in mouse 3T3-L1 adipocytes (Straub *et al.*, 2011). Similarly, margatoxin did not stimulate glucose utilization by rat epididymal or mesenteric adipocytes (Beeton *et al.*, 2006) when used at concentrations (1 or 100 nM) well above its EC₅₀ value (30 pM) for inhibition of Kv1.3 (Garcia-Calvo *et al.*, 1993). Upadhyay *et al.* (2013) have reported that the highly selective Kv1.3 inhibitor ShK-186 reduces obesity and hyperglycemia in mice fed on an obesogenic diet, but they too rule out an involvement of white adipocyte or skeletal muscle Kv1.3 channels, mainly because ShK-186 did not stimulate glucose uptake by white adipose tissue or skeletal muscle. ShK-186 doubled glucose uptake in brown adipose tissue, a site of high glucose uptake and uncoupled oxidative phosphorylation, making this a more likely explanation for the anti-obesity and anti-hyperglycemic effects of ShK-186, in their view. The same group had previously reported that ShK-186 also failed to stimulate glucose uptake by rat white adipocytes (Beeton *et al.*, 2006).

Although we do not believe that PAP-1 affected glucose uptake by inhibiting Kv1.3, we did detect Kv1.3 mRNA in murine adipose tissue and skeletal muscle (and also liver). Others appear to disagree as to whether Kv1.3 protein is expressed in murine adipose tissue, but this may be because one group used isolated epididymal adipocytes (Li *et al.*, 2006) and the other visceral adipose tissue (Upadhyay *et al.*, 2013). No Kv1.3 protein was detected in murine skeletal muscle (Upadhyay *et al.*, 2013) or in samples of adipose tissue and skeletal muscle from two normal and two type 2 diabetic human subjects (Straub *et al.*, 2011). One possible interpretation of these reports and our findings is that the expression of Kv1.3 is very low in adipose tissue and skeletal muscle, and is sometimes undetectable at the protein level, despite being detectable at the mRNA level. We found more Kv1.3 mRNA in tissues from *ob/ob* than wild-type mice, except for white adipose tissue, but given the relative amounts of adipose tissue in the wild-type and obese animals, the total amount of Kv1.3 mRNA in adipose tissue per animal may be higher in the *ob/ob* mice. We also found more Kv1.5 mRNA in liver and soleus muscle of *ob/ob* compared to lean mice. These results would be consistent with expression of either channel contributing to insulin resistance in *ob/ob* mice.

Levels of Kv1.5 mRNA appeared much higher than those of Kv1.3 in both adipocytes and soleus muscle. It is well-established that Kv1.5 is expressed in skeletal muscle (Kang *et al.*, 2009) but its expression in adipose tissue or adipocytes has not been reported. We cannot exclude the possibility that our results are influenced to some extent by the PCR reaction efficiency differing between genes, but this seems unlikely to alter our conclusion that the expression of Kv1.5 was much higher than that of Kv1.3 or Kv1.2 (Irwin *et al.*, 2012). In any event, irrespective of the precise differences in expression of the Kv genes, our findings raise the possibility that Kv1.5 was the channel that PAP-1 inhibited to stimulate glucose uptake and inhibit TNF α secretion. If so, Kv1.5 inhibitors might have potential in the treatment of type 2 diabetes. PAP-1 has been reported to inhibit Kv1.5 with an EC₅₀ value of 45 nM (Schmitz *et al.*, 2005), but it failed to stimulate glucose uptake in adipocytes when present at a concentration of 300 nM. The 6.7-fold lower EC₅₀ value of 45 nM was, however, measured with Kv1.5 from a different species and under very different

conditions: it was obtained by applying depolarizing pulses to mouse erythroleukaemia (MEL) cells stably transfected with human Kv1.5 and measuring the reduction in area under the current curve (*Grissmer et al., 1994*). By contrast, no depolarizing stimulus was applied in our work and we used mouse tissue. Whilst the EC₅₀ value of 2 nM for PAP-1 at Kv1.3 was also determined by an electrophysiological technique, it did use murine Kv1.3 (*Schmitz et al., 2005*), and it is less likely that the much higher (150-fold) discrepancy between this value and the minimum effective dose of PAP-1 for stimulation of glucose uptake can be explained in terms of the different test systems. PAP-1 is less potent at Kv1.2 (EC₅₀ = 250 nM) than Kv1.5 (*Schmitz et al., 2005*), and Kv1.2 mRNA could not be detected in adipocytes using Real Time RCR, ruling it out as a candidate target for PAP-1 in this tissue. We cannot rule out the possibility that Kv1.4, Kv1.6 or Kv1.7 could be the targets of PAP-1 in adipocytes and skeletal muscle, but Kv1.4 is poorly expressed in human adipocytes (*You et al., 2013*), and 100 nM margatoxin did not stimulate glucose uptake in rat epididymal adipocytes (*Beeton et al., 2006*), despite having an EC₅₀ value for inhibition of Kv1.5 of 5 nM (*Garcia-Calvo et al., 1993*).

We therefore conclude that although Kv1.3 mRNA could be detected in murine white adipose tissue, white adipocytes and red skeletal muscle, inhibition of Kv1.3 does not directly affect glucose uptake in white adipocytes or skeletal muscle. Blockade of Kv1.5 channels in white adipocytes or skeletal muscle might, however, stimulate glucose uptake. Studies using novel Kv1.5 inhibitors might be informative, but their selectivities have been given only relative to other cardiac K channels and not to other Kv1 channels (*Ford et al., 2013; Pavri et al., 2012*). We do not exclude the possibility that compounds might be useful in the treatment of obesity and insulin resistance, by inhibiting Kv1.3 in other tissues.

ACKNOWLEDGEMENTS

The authors are grateful to Dr Claire Cornick for assisting with the experiments, to Professor John Clapham for discussion of the manuscript and to Mrs Anita Roberts for help with the husbandry of the animals.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was funded by The University of Buckingham, supported in part by grant 05/045 from Xention Limited. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

The University of Buckingham.

Xention Limited: 05/045.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Robert A. Ngala, Mohamed S. Zaibi and Claire J. Stocker conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Kenneth Langlands conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, reviewed drafts of the paper.
- Jonathan R.S. Arch conceived and designed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper.
- Michael A. Cawthorne conceived and designed the experiments, reviewed drafts of the paper, manuscript revision and approval.

Animal Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

University of Buckingham Ethical Review Board. Animals were killed by an approved method to obtain tissues. Ethical approval numbers for housing and obtaining of tissues: 05/045; 06/016; 06/017; 14/010. Project licence PPL 70/7189.

REFERENCES

- Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, Andrews BS, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. 2006. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. *Proceedings of the National Academy of Sciences of the United States of America* **103**:17414–17419 DOI [10.1073/pnas.0605136103](https://doi.org/10.1073/pnas.0605136103).
- Calle MC, Fernandez ML. 2012. Inflammation and type 2 diabetes. *Diabetes & Metabolism* **38**:183–191 DOI [10.1016/j.diabet.2011.11.006](https://doi.org/10.1016/j.diabet.2011.11.006).
- Choi BH, Hahn SJ. 2010. Kv1.3: a potential pharmacological target for diabetes. *ACTA Pharmacologica Sinica* **31**:1031–1035 DOI [10.1038/aps.2010.133](https://doi.org/10.1038/aps.2010.133).
- Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath Z, Matschke K, Varro A, Ravens U. 2013. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. *Journal of Cardiovascular Pharmacology* **61**:408–415 DOI [10.1097/FJC.0b013e31828780eb](https://doi.org/10.1097/FJC.0b013e31828780eb).
- Galvez BG, San Martin N, Rodriguez C. 2009. TNF-alpha is required for the attraction of mesenchymal precursors to white adipose tissue in *ob/ob* mice. *PLoS ONE* **4**:e4444 DOI [10.1371/journal.pone.0004444](https://doi.org/10.1371/journal.pone.0004444).
- Garcia-Calvo M, Leonard RJ, Novick J, Stevens SP, Schmalhofer W, Kaczorowski GJ, Garcia ML. 1993. Purification, characterization, and biosynthesis of margatoxin, a component of *Centruroides margaritatus* venom that selectively inhibits voltage-dependent potassium channels. *Journal of Biological Chemistry* **268**:18866–18874.

- Grande M, Suarez E, Vicente R, Canto C, Coma M, Tamkun MM, Zorzano A, Guma A, Felipe A. 2003. Voltage-dependent K⁺ channel beta subunits in muscle: differential regulation during postnatal development and myogenesis. *Journal of Cellular Physiology* 195:187–193 DOI 10.1002/jcp.10203.
- Grissmer S, Nguyen AN, Aiyar J, Hanson DC, Mather RJ, Gutman GA, Kamilowicz MJ, Auperin DD, Chandy KG. 1994. Pharmacological characterization of five cloned voltage-gated K⁺ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. *Molecular Pharmacology* 45:1227–1234.
- Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarrubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kupersmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O’Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS. 2003. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. *Pharmacological Reviews* 55:583–586 DOI 10.1124/pr.55.4.9.
- Irwin PL, Nguyen LH, Chen CY, Uhlich GA, Paoli GC. 2012. A method for correcting standard-based real-time PCR DNA quantitation when the standard’s polymerase reaction efficiency is significantly different from that of the unknown’s. *Analytical and Bioanalytical Chemistry* 402:2713–2725 DOI 10.1007/s00216-012-5737-9.
- Kang LS, Kim S, Dominguez 2nd JM, Sindler AL, Dick GM, Muller-Delp JM. 2009. Aging and muscle fiber type alter K⁺ channel contributions to the myogenic response in skeletal muscle arterioles. *Journal of Applied Physiology (1985)* 107:389–398 DOI 10.1152/japophysiol.91245.2008.
- Kashiwagi A, Huecksteadt TP, Foley JE. 1983. The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. *Journal of Biological Chemistry* 258:13685–13692.
- Li Y, Wang P, Xu J, Desir GV. 2006. Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca²⁺-dependent mechanism. *American Journal of Physiological Cell Physiology* 290:C345–C351 DOI 10.1152/ajpcell.00091.2005.
- Ngala RA, O’Dowd J, Wang SJ, Agarwal A, Stocker C, Cawthorne MA, Arch JR. 2008. Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and β_2 -adrenoceptor mechanisms. *British Journal of Pharmacology* 155:395–406 DOI 10.1038/bjp.2008.244.
- Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. 2012. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. *Circulation: Arrhythmia and Electrophysiology* 5:1193–1201 DOI 10.1161/CIRCEP.111.969782.
- Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. 2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. *Molecular Pharmacology* 68:1254–1270 DOI 10.1124/mol.105.015669.
- Straub SV, Perez SM, Tan B, Coughlan KA, Trebino CE, Cosgrove P, Buxton JM, Kreeger JM, Jackson VM. 2011. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. *American Journal of Physiology, Endocrinology and Metabolism* 301:E380–E390 DOI 10.1152/ajpendo.00076.2011.

- Tschritter O, Machicao F, Stefan N, Schafer S, Weigert C, Staiger H, Spieth C, Haring HU, Fritsche A. 2006.** A new variant in the human Kv1.3 gene is associated with low insulin sensitivity and impaired glucose tolerance. *Journal of Clinical Endocrinology and Metabolism* **91**:654–658 DOI [10.1210/jc.2005-0725](https://doi.org/10.1210/jc.2005-0725).
- Tucker K, Overton JM, Fadool DA. 2008.** Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. *International Journal of Obesity* **32**:1222–1232 DOI [10.1038/ijo.2008.77](https://doi.org/10.1038/ijo.2008.77).
- Upadhyay SK, Eckel-Mahan KL, Mirbolooki MR, Tjong I, Griffey SM, Schmunk G, Koehne A, Halbout B, Iadonato S, Pedersen B, Borrelli E, Wang PH, Mukherjee J, Sassone-Corsi P, Chandy KG. 2013.** Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance. *Proceedings of the National Academy of Sciences of the United States of America* **110**:E2239–E2248 DOI [10.1073/pnas.1221206110](https://doi.org/10.1073/pnas.1221206110).
- Wargent ET, O’Dowd JF, Zaibi MS, Gao D, Bing C, Trayhurn P, Cawthorne MA, Arch JR, Stocker CJ. 2013.** Contrasts between the effects of zinc-alpha2-glycoprotein, a putative beta3/2-adrenoceptor agonist and the beta3/2-adrenoceptor agonist BRL35135 in C57Bl/6 (*ob/ob*) mice. *Journal of Endocrinology* **216**:157–168 DOI [10.1530/JOE-12-0402](https://doi.org/10.1530/JOE-12-0402).
- Xu J, Koni PA, Wang P, Li G, Kaczmarek L, Wu Y, Li Y, Flavell RA, Desir GV. 2003.** The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. *Human Molecular Genetics* **12**:551–559 DOI [10.1093/hmg/ddg049](https://doi.org/10.1093/hmg/ddg049).
- Xu J, Wang P, Li Y, Li G, Kaczmarek LK, Wu Y, Koni PA, Flavell RA, Desir GV. 2004.** The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. *Proceedings of the National Academy of Sciences of the United States of America* **101**:3112–3117 DOI [10.1073/pnas.0308450100](https://doi.org/10.1073/pnas.0308450100).
- You MH, Song MS, Lee SK, Ryu PD, Lee SY, Kim DY. 2013.** Voltage-gated K⁺ channels in adipogenic differentiation of bone marrow-derived human mesenchymal stem cells. *ACTA Pharmacologica Sinica* **34**:129–136 DOI [10.1038/aps.2012.142](https://doi.org/10.1038/aps.2012.142).
- Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR. 2010.** Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. *FEBS Letters* **584**:2381–2386 DOI [10.1016/j.febslet.2010.04.027](https://doi.org/10.1016/j.febslet.2010.04.027).